First Trust Advisors LP Grows Stock Holdings in LeMaitre Vascular, Inc. $LMAT

Key Points

• First Trust Advisors LP boosted its stake in LeMaitre Vascular by 35.4% in Q3 to 828,947 shares, now owning 3.66% of the company (about $72.5M), and institutional investors hold 84.64% of the stock.
• LeMaitre beat quarterly estimates with $0.68 EPS (vs. $0.67) and $64.45M revenue (up 15.7% YoY), and issued FY2026 guidance of $2.810–3.010 EPS and Q1 guidance of $0.640–0.690.
• Significant insider selling occurred—CEO George W. LeMaitre sold 55,930 shares (~$6.03M) and insiders sold 215,438 shares (~$23.06M) in the last 90 days—while the company raised its quarterly dividend to $0.25 (annualized $1.00, ~0.9% yield).

First Trust Advisors LP boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 35.4% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 828,947 shares of the medical instruments supplier's stock after acquiring an additional 216,919 shares during the period. First Trust Advisors LP owned 3.66% of LeMaitre Vascular worth $72,541,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Aptus Capital Advisors LLC lifted its position in LeMaitre Vascular by 15.1% during the 3rd quarter. Aptus Capital Advisors LLC now owns 67,492 shares of the medical instruments supplier's stock worth $5,906,000 after acquiring an additional 8,871 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of LeMaitre Vascular by 0.4% in the third quarter. Dimensional Fund Advisors LP now owns 462,679 shares of the medical instruments supplier's stock valued at $40,486,000 after purchasing an additional 1,677 shares during the period. Segall Bryant & Hamill LLC raised its stake in shares of LeMaitre Vascular by 2.9% during the third quarter. Segall Bryant & Hamill LLC now owns 85,159 shares of the medical instruments supplier's stock worth $7,452,000 after purchasing an additional 2,364 shares during the last quarter. Bahl & Gaynor Inc. raised its stake in shares of LeMaitre Vascular by 1.7% during the third quarter. Bahl & Gaynor Inc. now owns 124,981 shares of the medical instruments supplier's stock worth $10,937,000 after purchasing an additional 2,066 shares during the last quarter. Finally, Caitlin John LLC lifted its holdings in shares of LeMaitre Vascular by 2.3% during the third quarter. Caitlin John LLC now owns 15,984 shares of the medical instruments supplier's stock worth $1,399,000 after purchasing an additional 366 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on LMAT. Citizens Jmp lifted their price objective on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a "market outperform" rating in a research report on Thursday, February 26th. Cantor Fitzgerald restated a "neutral" rating and issued a $95.00 target price on shares of LeMaitre Vascular in a research note on Monday, November 10th. Wells Fargo & Company lifted their target price on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an "equal weight" rating in a report on Thursday, February 26th. Roth Mkm reiterated a "buy" rating and set a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Finally, Zacks Research cut shares of LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a report on Thursday, January 1st. Three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $105.80.

Insider Buying and Selling

In other news, insider Trent G. Kamke sold 1,044 shares of the business's stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $110.29, for a total transaction of $115,142.76. Following the sale, the insider owned 6,677 shares of the company's stock, valued at $736,406.33. The trade was a 13.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO George W. Lemaitre sold 55,930 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $107.81, for a total value of $6,029,813.30. Following the completion of the sale, the chief executive officer owned 1,476,500 shares in the company, valued at approximately $159,181,465. This represents a 3.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 215,438 shares of company stock valued at $23,062,911. Corporate insiders own 9.50% of the company's stock.

LeMaitre Vascular Trading Up 2.5%

Shares of LMAT stock opened at $110.07 on Tuesday. The business's fifty day moving average price is $89.84 and its 200 day moving average price is $88.81. The firm has a market capitalization of $2.51 billion, a PE ratio of 43.85, a P/E/G ratio of 3.09 and a beta of 0.66. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.01. The company had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.LeMaitre Vascular's quarterly revenue was up 15.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 26th. Investors of record on Thursday, March 12th will be issued a dividend of $0.25 per share. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, March 12th. LeMaitre Vascular's payout ratio is presently 31.87%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.